Our results are reinforced by other studies that have reported that BRAF mutations are associated with higher expression of the PD-L1 protein in thyroid cancer, and that increased PD-L1 expression is significantly associated with disease recurrence and poor survival [19,20]. Here, CD274 is linked to thyroid gland carcinoma.